Study shows connection between the ancestry & the molecular makeup of cancer

May 11, 2020

Questions about the genealogical imprint of tumors have hovered over cancer research since the completion of the Human Genome Project in 2003. Is liver cancer different at a basic, molecular level in people of African descent than people of European descent? Does breast cancer have a different genetic profile in East Asians than Native Americans?

A new paper by researchers from the NCI Cancer Genome Analysis Network, a collaborative group with investigators in the U.S., Canada and Europe, provides the most comprehensive look to date at the effect of ancestry on the molecular makeup of normal and cancerous tissues. Drawing on data from The Cancer Genome Atlas (TCGA) involving 10,678 patients and 33 cancer types, the investigators found that ancestry was tied to variations in hundreds of genes, but that the most important of these differences were linked to specific tissue types. The study is being published online today by Cancer Cell.

"We found that in patients of different ancestries, the molecular features corresponding to those differences were largely confined to specific organs and tissue types," said Rameen Beroukhim, MD, PhD, of Dana-Farber and the Broad Institute, the co-senior author of the study with Andrew Cherniack, PhD, group leader at Dana-Farber and the Broad Institute. "This suggests that tracking the molecular effects of ancestry - both in normal and cancer tissue - needs to take a tissue-by-tissue approach."

Among the researchers' specific findings:In the study, investigators used a variety of molecular techniques to determine the ancestry of the patients whose tissue samples were analyzed. Patients were classified as being primarily of European, East Asian, African, Native/Latin American, or South Asian descent. Patients whose ancestry was at least 20% mixed were classified as being of admixed descent. (These patients were subcategorized by their primary ancestry, such as African-Admixed, European-Admixed, etc.) As a group, the patients had 33 cancer types, 13 of which were further divided into subtypes.

TCGA had conducted a deep analysis of each patient's tissue, testing cancerous and normal cells for a range of molecular features. These included mutations (miscopied sections of DNA); patterns of DNA methylation (a process that influences whether genes are switched on or off); messenger RNA (a molecule that carries a transcribed version of DNA and is indicative of gene activity); and microRNA (a form of RNA that assists or hampers gene activity). The NCI Cancer Genome Analysis Network investigators used this data to see whether differences in any of these features reflected differences in ancestry.

"We found that ancestry-associated differences spanned all of these features and were present in hundreds of different genes," Cherniack stated. "It turned out, though, that the most significant differences - the ones that affect how cells function and interact with the rest of the body - were profoundly tissue-specific." Although ancestry affected molecular features in most cancer types, these effects were not shared across cancer types. Molecular differences in lung cancers that were traceable to African ancestry, for example, were not found in breast, pancreatic, or other cancers.

The data also enabled investigators to ask whether the ancestry-related features of normal cells carried over into the cancerous versions of those cells - whether the molecular particularities of lung cells in people of European extraction for example, are also found in the lung cancer cells of such individuals. They found that this was overwhelmingly the case. "Most of the differences in the normal tissues of people with specific ancestries are recapitulated in cancer," Beroukhim stated. Moreover, evidence suggests that some of these differences may contribute to the development of certain cancers in people with similar backgrounds.

Having access to data from patients of mixed lineage proved to be an asset, the study authors say. Investigators conducted their initial analysis in patients whose ancestry was at least 80% within one of the five genealogical groups. They followed this with a similar analysis of data from the admixed populations. "When the results of the two analyses jibed - when molecular differences specific to one ancestral group also appear in patients whose ancestry is a combination of that group and others - it was particularly strong evidence of the validity of the original finding." said one of the study's co-lead authors, Jian Carrot-Zhang, PhD, postdoctoral research fellow of the Meyerson group at Dana-Farber and the Broad. "The patients of mixed background were a particularly powerful group in which to study the molecular effects of ancestry in cancer," Beroukhim stated. "It helped us narrow down which regions of the genome contribute to these differences."

The comprehensive nature of the study revealed some of the shortcomings of previous efforts to link ethnicity and ancestry to molecular elements of cells. For one, such studies tended to lump various subtypes of cancer together, Beroukhim said, despite the fact that certain subtypes are more common in certain ancestries than others. Some of the techniques used to dissect molecular features may also have skewed the results of previous studies.

Researchers have yet to determine whether the molecular differences between ancestries result from environmental factors or genetic factors. However, they did identify genetic differences between ancestries that could explain many of their findings.

"Our findings point to a need for more samples from diverse ancestries to conduct a truly comprehensive ancestry analysis, especially of normal tissues," Beroukhim remarks. "This study represents an important step in that direction."
The co-lead authors of the study are Nyasha Chambwe, PhD, and Theo A. Knijnenburg, PhD, of the Institute for Systems Biology, Seattle, Wash.; Jeffrey S. Damrauer, of Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; A. Gordon Robertson, PhD, of British Columbia Cancer Agency; Christina Yau, PhD, of Buck Institute for Research on Aging, Novato, Calif., and the University of California, San Francisco; Wanding Zhou, PhD, of the Van Andel Research Institute, Grand Rapids, Mich.; Ashton C. Berger, of Dana-Farber and the Broad Institute; Kuan-lin Huang, PhD, of Icahn School of Medicine at Mount Sinai, New York, N.Y.; and Justin Newberg, PhD, of Foundation Medicine, Inc., Cambridge, Mass. Co-authors are: R. Jay Mashl, PhD, of Washington University in St. Louis, St. Louis, Mo.; Alessandro Romanel, PhD, and Francesca Demichelis, PhD, of University of Trento, Italy; Rosalyn W. Sayaman, PhD, and Elad Ziv, MD, of Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, and Beckman Research Institute, City of Hope, Duarte, Calif.; Ina Felau, MS, Anab Kemal, and Jean C. Zenklusen, PhD, of the National Cancer Institute; Garrett Frampton, PhD, of Foundation Medicine, Inc., Cambridge, Mass.; Seunghun Han, of Dana-Farber; Katherine A. Hoadley, PhD, of Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; Peter W. Laird, PhD, and Hui Shen, PhD, of Van Andel Research Institute; Alexander J. Lazar, MD, PhD, and Xiuning Le, MD, of The University of Texas M.D. Anderson Cancer Center; Ninad Oak, PhD, of St. Jude Children's Research Hospital and Baylor College of Medicine; Christopher K. Wong, MS, of University of California, Santa Cruz; and the Cancer Genome Atlas Analysis Network.

Funding for the study was provided by the National Cancer Institute (U24 grants CA210999, CA210974, CA211006, CA210949, CA210978, CA210952, CA210989, CA210957, CA210990, CA211000, CA210950, CA210969, CA210988, and K24CA169004 and R01CA1845851).

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 5 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.

Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

About the Broad Institute of MIT and Harvard

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to

Dana-Farber Cancer Institute

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to